Working… Menu

Cosopt Versus Xalatan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00273429
Recruitment Status : Completed
First Posted : January 9, 2006
Last Update Posted : January 9, 2007
Information provided by:
Pharmaceutical Research Network

Brief Summary:
To compare the 24-hour efficacy and safety, measured every three hours, of the dorzolamide/timolol fixed combination given twice daily versus latanoprost and placebo each given once daily.

Condition or disease Intervention/treatment Phase
Open-Angle Glaucoma Ocular Hypertension Drug: timolol maleate 0.5% Drug: dorzolamide/timolol maleate fixed combination Drug: latanoprost 0.005% Drug: placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : April 2005
Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults with primary open-angle, pigmentary, or exfoliation glaucoma, or ocular hypertenstion
  • intraocular pressure should be 22 to 30 mm Hg inclusive on timolol BID at the 08:00 H
  • ETDRS visual acuity must be 1.0 or better in both eyes

Exclusion Criteria:

  • any contraindications to study medications
  • any anticipated change in systemic hypertensive therapy during the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00273429

Layout table for location information
United States, Florida
Central Florida Eye Associates
Lakeland, Florida, United States, 33805
United States, Illinois
Midwest Eye Center SC
Bourbonnais, Illinois, United States, 60914
Sponsors and Collaborators
Pharmaceutical Research Network
Layout table for investigator information
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Jay Mulaney, MD Central Florida Eye Associates
Principal Investigator: Sriram Sonty, MD, FACS Midwest Eye Center SC
Layout table for additonal information Identifier: NCT00273429    
Other Study ID Numbers: PRN 04-015
First Posted: January 9, 2006    Key Record Dates
Last Update Posted: January 9, 2007
Last Verified: January 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Maleic acid
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Enzyme Inhibitors
Ophthalmic Solutions
Pharmaceutical Solutions
Carbonic Anhydrase Inhibitors